Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target ...

Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results ...

Orphan Drug Tag For Mersana's Gastric Cancer Candidate Vandana Singh Mersana Therapeutics Director Andrew Hack Reported Purchase of 350,000 Shares @ Avg Price of $3.25/Share in Form 4 Filing on ...

The U.S. dollar rallied on Friday after data showed the world's largest economy created more jobs than expected last month, reinforcing expectations that the Federal Reserve will pause its rate ...

U.S. President-elect Donald Trump will not go to jail or face any other punishment for his criminal conviction stemming from hush money paid to a porn star, a judge ruled on Friday but said Trump ...

Supreme Court Seems Poised to Uphold Law That Could Ban TikTok The justices are expected to rule quickly in the case, which pits national security concerns about China against free speech ...